Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibacterial activity of extracellular compounds produced by a <italic>Pseudomonas</italic> strain against methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) strains</title><author><name sortKey="Cardozo, Viviane F" sort="Cardozo, Viviane F" uniqKey="Cardozo V" first="Viviane F" last="Cardozo">Viviane F. Cardozo</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Oliveira, Admilton G" sort="Oliveira, Admilton G" uniqKey="Oliveira A" first="Admilton G" last="Oliveira">Admilton G. Oliveira</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Nishio, Erick K" sort="Nishio, Erick K" uniqKey="Nishio E" first="Erick K" last="Nishio">Erick K. Nishio</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Perugini, Marcia Re" sort="Perugini, Marcia Re" uniqKey="Perugini M" first="Marcia Re" last="Perugini">Marcia Re Perugini</name><affiliation><nlm:aff id="I2">Department of Pathology, Clinical Analysis and Toxicological, University of Londrina State, Londrina, PR CP 86038-440, Brazil</nlm:aff></affiliation></author><author><name sortKey="Andrade, Celia Gtj" sort="Andrade, Celia Gtj" uniqKey="Andrade C" first="Célia Gtj" last="Andrade">Célia Gtj Andrade</name><affiliation><nlm:aff id="I3">Department of General Biology, University of Londrina State, Londrina, PR CP 86051-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Silveira, Wanderley D" sort="Silveira, Wanderley D" uniqKey="Silveira W" first="Wanderley D" last="Silveira">Wanderley D. Silveira</name><affiliation><nlm:aff id="I4">Department of Genetics, Evolution and Bioagent, Biology Institute, Campinas State University (UNICAMP), Campinas, SP CP 13083-970, Brazil</nlm:aff></affiliation></author><author><name sortKey="Duran, Nelson" sort="Duran, Nelson" uniqKey="Duran N" first="Nelson" last="Durán">Nelson Durán</name><affiliation><nlm:aff id="I5">Department of Physical Chemistry, Chemistry Institute Campinas State University (UNICAMP), Campinas, SP CP 13083-970, Brazil</nlm:aff></affiliation></author><author><name sortKey="Andrade, Galdino" sort="Andrade, Galdino" uniqKey="Andrade G" first="Galdino" last="Andrade">Galdino Andrade</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Kobayashi, Renata Kt" sort="Kobayashi, Renata Kt" uniqKey="Kobayashi R" first="Renata Kt" last="Kobayashi">Renata Kt Kobayashi</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Nakazato, Gerson" sort="Nakazato, Gerson" uniqKey="Nakazato G" first="Gerson" last="Nakazato">Gerson Nakazato</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23773484</idno><idno type="pmc">3695862</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695862</idno><idno type="RBID">PMC:3695862</idno><idno type="doi">10.1186/1476-0711-12-12</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000A86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Antibacterial activity of extracellular compounds produced by a <italic>Pseudomonas</italic> strain against methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) strains</title><author><name sortKey="Cardozo, Viviane F" sort="Cardozo, Viviane F" uniqKey="Cardozo V" first="Viviane F" last="Cardozo">Viviane F. Cardozo</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Oliveira, Admilton G" sort="Oliveira, Admilton G" uniqKey="Oliveira A" first="Admilton G" last="Oliveira">Admilton G. Oliveira</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Nishio, Erick K" sort="Nishio, Erick K" uniqKey="Nishio E" first="Erick K" last="Nishio">Erick K. Nishio</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Perugini, Marcia Re" sort="Perugini, Marcia Re" uniqKey="Perugini M" first="Marcia Re" last="Perugini">Marcia Re Perugini</name><affiliation><nlm:aff id="I2">Department of Pathology, Clinical Analysis and Toxicological, University of Londrina State, Londrina, PR CP 86038-440, Brazil</nlm:aff></affiliation></author><author><name sortKey="Andrade, Celia Gtj" sort="Andrade, Celia Gtj" uniqKey="Andrade C" first="Célia Gtj" last="Andrade">Célia Gtj Andrade</name><affiliation><nlm:aff id="I3">Department of General Biology, University of Londrina State, Londrina, PR CP 86051-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Silveira, Wanderley D" sort="Silveira, Wanderley D" uniqKey="Silveira W" first="Wanderley D" last="Silveira">Wanderley D. Silveira</name><affiliation><nlm:aff id="I4">Department of Genetics, Evolution and Bioagent, Biology Institute, Campinas State University (UNICAMP), Campinas, SP CP 13083-970, Brazil</nlm:aff></affiliation></author><author><name sortKey="Duran, Nelson" sort="Duran, Nelson" uniqKey="Duran N" first="Nelson" last="Durán">Nelson Durán</name><affiliation><nlm:aff id="I5">Department of Physical Chemistry, Chemistry Institute Campinas State University (UNICAMP), Campinas, SP CP 13083-970, Brazil</nlm:aff></affiliation></author><author><name sortKey="Andrade, Galdino" sort="Andrade, Galdino" uniqKey="Andrade G" first="Galdino" last="Andrade">Galdino Andrade</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Kobayashi, Renata Kt" sort="Kobayashi, Renata Kt" uniqKey="Kobayashi R" first="Renata Kt" last="Kobayashi">Renata Kt Kobayashi</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author><author><name sortKey="Nakazato, Gerson" sort="Nakazato, Gerson" uniqKey="Nakazato G" first="Gerson" last="Nakazato">Gerson Nakazato</name><affiliation><nlm:aff id="I1">Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</nlm:aff></affiliation></author></analytic><series><title level="j">Annals of Clinical Microbiology and Antimicrobials</title><idno type="eISSN">1476-0711</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The emergence of multidrug-resistant bacteria is a world health problem. <italic>Staphylococcus aureus,</italic> including methicillin-resistant <italic>S. aureus</italic> (MRSA) strains, is one of the most important human pathogens associated with hospital and community-acquired infections. The aim of this work was to evaluate the antibacterial activity of a <italic>Pseudomonas aeruginosa</italic>-derived compound against MRSA strains.</p></sec><sec><title>Methods</title><p>Thirty clinical MRSA strains were isolated, and three standard MRSA strains were evaluated. The extracellular compounds were purified by vacuum liquid chromatography. Evaluation of antibacterial activity was performed by agar diffusion technique, determination of the minimal inhibitory concentration, curve of growth and viability and scanning electron microscopy. Interaction of an extracellular compound with silver nanoparticle was studied to evaluate antibacterial effect.</p></sec><sec><title>Results</title><p>The F3 (ethyl acetate) and F3d (dichloromethane- ethyl acetate) fractions demonstrated antibacterial activity against the MRSA strains. Phenazine-1-carboxamide was identified and purified from the F3d fraction and demonstrated slight antibacterial activity against MRSA, and synergic effect when combined with silver nanoparticles produced by <italic>Fusarium oxysporum</italic>. Organohalogen compound was purified from this fraction showing high antibacterial effect. Using scanning electron microscopy, we show that the F3d fraction caused morphological changes to the cell wall of the MRSA strains.</p></sec><sec><title>Conclusions</title><p>These results suggest that <italic>P. aeruginosa</italic>-produced compounds such as phenazines have inhibitory effects against MRSA and may be a good alternative treatment to control infections caused by MRSA.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Buke, C" uniqKey="Buke C">C Buke</name></author><author><name sortKey="Armand Lefevre, L" uniqKey="Armand Lefevre L">L Armand-Lefevre</name></author><author><name sortKey="Lolom, I" uniqKey="Lolom I">I Lolom</name></author><author><name sortKey="Guerinot, W" uniqKey="Guerinot W">W Guerinot</name></author><author><name sortKey="Deblangy, C" uniqKey="Deblangy C">C Deblangy</name></author><author><name sortKey="Ruimy, R" uniqKey="Ruimy R">R Ruimy</name></author><author><name sortKey="Andremont, A" uniqKey="Andremont A">A Andremont</name></author><author><name sortKey="Lucet, Jc" uniqKey="Lucet J">JC Lucet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strateva, T" uniqKey="Strateva T">T Strateva</name></author><author><name sortKey="Ouzounova Raykova, V" uniqKey="Ouzounova Raykova V">V Ouzounova-Raykova</name></author><author><name sortKey="Markova, B" uniqKey="Markova B">B Markova</name></author><author><name sortKey="Todorova, A" uniqKey="Todorova A">A Todorova</name></author><author><name sortKey="Marteva Proevska, Y" uniqKey="Marteva Proevska Y">Y Marteva-Proevska</name></author><author><name sortKey="Mitov, I" uniqKey="Mitov I">I Mitov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stefani, S" uniqKey="Stefani S">S Stefani</name></author><author><name sortKey="Varaldo, Pe" uniqKey="Varaldo P">PE Varaldo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rodriguez Noriega, E" uniqKey="Rodriguez Noriega E">E Rodríguez-Noriega</name></author><author><name sortKey="Seas, C" uniqKey="Seas C">C Seas</name></author><author><name sortKey="Guzman Blanco, M" uniqKey="Guzman Blanco M">M Guzmán-Blanco</name></author><author><name sortKey="Mejia, C" uniqKey="Mejia C">C Mejía</name></author><author><name sortKey="Alvarez, C" uniqKey="Alvarez C">C Alvarez</name></author><author><name sortKey="Bavestrello, L" uniqKey="Bavestrello L">L Bavestrello</name></author><author><name sortKey="Zurita, J" uniqKey="Zurita J">J Zurita</name></author><author><name sortKey="Labarca, J" uniqKey="Labarca J">J Labarca</name></author><author><name sortKey="Luna, Cm" uniqKey="Luna C">CM Luna</name></author><author><name sortKey="Salles, Mj" uniqKey="Salles M">MJ Salles</name></author><author><name sortKey="Gotuzzo, E" uniqKey="Gotuzzo E">E Gotuzzo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, As" uniqKey="Lee A">AS Lee</name></author><author><name sortKey="Huttner, B" uniqKey="Huttner B">B Huttner</name></author><author><name sortKey="Harbarth, S" uniqKey="Harbarth S">S Harbarth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weese, Js" uniqKey="Weese J">JS Weese</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Tc" uniqKey="Smith T">TC Smith</name></author><author><name sortKey="Pearson, N" uniqKey="Pearson N">N Pearson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sader, Hs" uniqKey="Sader H">HS Sader</name></author><author><name sortKey="Jones, Rn" uniqKey="Jones R">RN Jones</name></author><author><name sortKey="Gales, Ac" uniqKey="Gales A">AC Gales</name></author><author><name sortKey="Silva, Jb" uniqKey="Silva J">JB Silva</name></author><author><name sortKey="Pignatari, Ac" uniqKey="Pignatari A">AC Pignatari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oliveira, G" uniqKey="Oliveira G">G Oliveira</name></author><author><name sortKey="Faria, J" uniqKey="Faria J">J Faria</name></author><author><name sortKey="Levy, C" uniqKey="Levy C">C Levy</name></author><author><name sortKey="Mamizuka, Em" uniqKey="Mamizuka E">EM Mamizuka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karchmer, Tb" uniqKey="Karchmer T">TB Karchmer</name></author><author><name sortKey="Durbin, Lj" uniqKey="Durbin L">LJ Durbin</name></author><author><name sortKey="Simonton, Bm" uniqKey="Simonton B">BM Simonton</name></author><author><name sortKey="Farr, Bm" uniqKey="Farr B">BM Farr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laupland, Kb" uniqKey="Laupland K">KB Laupland</name></author><author><name sortKey="Lee, H" uniqKey="Lee H">H Lee</name></author><author><name sortKey="Gregson, Db" uniqKey="Gregson D">DB Gregson</name></author><author><name sortKey="Manns, Bj" uniqKey="Manns B">BJ Manns</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cris Stomo, Mi" uniqKey="Cris Stomo M">MI Crisóstomo</name></author><author><name sortKey="Westh, H" uniqKey="Westh H">H Westh</name></author><author><name sortKey="Tomasz, A" uniqKey="Tomasz A">A Tomasz</name></author><author><name sortKey="Chung, M" uniqKey="Chung M">M Chung</name></author><author><name sortKey="Oliveira, Dc" uniqKey="Oliveira D">DC Oliveira</name></author><author><name sortKey="De Lencastre, H" uniqKey="De Lencastre H">H de Lencastre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Eill, Aj" uniqKey="O Eill A">AJ O’Neill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jamil, M" uniqKey="Jamil M">M Jamil</name></author><author><name sortKey="Ul Haq, I" uniqKey="Ul Haq I">I Ul Haq</name></author><author><name sortKey="Mirza, B" uniqKey="Mirza B">B Mirza</name></author><author><name sortKey="Qayyum, M" uniqKey="Qayyum M">M Qayyum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, Jg" uniqKey="Choi J">JG Choi</name></author><author><name sortKey="Kang, Oh" uniqKey="Kang O">OH Kang</name></author><author><name sortKey="Chae, Hs" uniqKey="Chae H">HS Chae</name></author><author><name sortKey="Obiang Obounou, B" uniqKey="Obiang Obounou B">B Obiang-Obounou</name></author><author><name sortKey="Lee, Ys" uniqKey="Lee Y">YS Lee</name></author><author><name sortKey="Oh, Yc" uniqKey="Oh Y">YC Oh</name></author><author><name sortKey="Kim, Ms" uniqKey="Kim M">MS Kim</name></author><author><name sortKey="Shin, Dw" uniqKey="Shin D">DW Shin</name></author><author><name sortKey="Kim, Ja" uniqKey="Kim J">JA Kim</name></author><author><name sortKey="Kim, Yh" uniqKey="Kim Y">YH Kim</name></author><author><name sortKey="Kwon, Dy" uniqKey="Kwon D">DY Kwon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ifesan, Bo" uniqKey="Ifesan B">BO Ifesan</name></author><author><name sortKey="Hamtasin, C" uniqKey="Hamtasin C">C Hamtasin</name></author><author><name sortKey="Mahabusarakam, W" uniqKey="Mahabusarakam W">W Mahabusarakam</name></author><author><name sortKey="Voravuthikunchai, Sp" uniqKey="Voravuthikunchai S">SP Voravuthikunchai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zuo, Gy" uniqKey="Zuo G">GY Zuo</name></author><author><name sortKey="Meng, Fy" uniqKey="Meng F">FY Meng</name></author><author><name sortKey="Hao, Xy" uniqKey="Hao X">XY Hao</name></author><author><name sortKey="Zhang, Yl" uniqKey="Zhang Y">YL Zhang</name></author><author><name sortKey="Wang, Gc" uniqKey="Wang G">GC Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pereira, Em" uniqKey="Pereira E">EM Pereira</name></author><author><name sortKey="Machado, Tb" uniqKey="Machado T">TB Machado</name></author><author><name sortKey="Leal, Icr" uniqKey="Leal I">ICR Leal</name></author><author><name sortKey="Jesus, Dm" uniqKey="Jesus D">DM Jesus</name></author><author><name sortKey="Damaso, Cra" uniqKey="Damaso C">CRA Damaso</name></author><author><name sortKey="Pinto, Av" uniqKey="Pinto A">AV Pinto</name></author><author><name sortKey="De Marval, Mc" uniqKey="De Marval M">MC de Marval</name></author><author><name sortKey="Kuster, Rm" uniqKey="Kuster R">RM Kuster</name></author><author><name sortKey="Dos Santos, Krn" uniqKey="Dos Santos K">KRN dos Santos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hashizume, H" uniqKey="Hashizume H">H Hashizume</name></author><author><name sortKey="Igarashi, M" uniqKey="Igarashi M">M Igarashi</name></author><author><name sortKey="Sawa, R" uniqKey="Sawa R">R Sawa</name></author><author><name sortKey="Adachi, H" uniqKey="Adachi H">H Adachi</name></author><author><name sortKey="Nishimura, Y" uniqKey="Nishimura Y">Y Nishimura</name></author><author><name sortKey="Akamatsu, Y" uniqKey="Akamatsu Y">Y Akamatsu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cazoto, Ll" uniqKey="Cazoto L">LL Cazoto</name></author><author><name sortKey="Martins, D" uniqKey="Martins D">D Martins</name></author><author><name sortKey="Ribeiro, Mg" uniqKey="Ribeiro M">MG Ribeiro</name></author><author><name sortKey="Duran, N" uniqKey="Duran N">N Durán</name></author><author><name sortKey="Nakazato, G" uniqKey="Nakazato G">G Nakazato</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ding, R" uniqKey="Ding R">R Ding</name></author><author><name sortKey="Wu, Xc" uniqKey="Wu X">XC Wu</name></author><author><name sortKey="Qian, Cd" uniqKey="Qian C">CD Qian</name></author><author><name sortKey="Teng, Y" uniqKey="Teng Y">Y Teng</name></author><author><name sortKey="Li, O" uniqKey="Li O">O Li</name></author><author><name sortKey="Zhan, Zj" uniqKey="Zhan Z">ZJ Zhan</name></author><author><name sortKey="Zhao, Yh" uniqKey="Zhao Y">YH Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oliveira, Ag" uniqKey="Oliveira A">AG Oliveira</name></author><author><name sortKey="Murate, Ls" uniqKey="Murate L">LS Murate</name></author><author><name sortKey="Spago, Fr" uniqKey="Spago F">FR Spago</name></author><author><name sortKey="Lopes, Lp" uniqKey="Lopes L">LP Lopes</name></author><author><name sortKey="Beranger, Jpo" uniqKey="Beranger J">JPO Beranger</name></author><author><name sortKey="San Martin, Jab" uniqKey="San Martin J">JAB San Martin</name></author><author><name sortKey="Nogueira, Ma" uniqKey="Nogueira M">MA Nogueira</name></author><author><name sortKey="Mello, Jcp" uniqKey="Mello J">JCP Mello</name></author><author><name sortKey="Andrade, Cgtj" uniqKey="Andrade C">CGTJ Andrade</name></author><author><name sortKey="Andrade, G" uniqKey="Andrade G">G Andrade</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuroda, M" uniqKey="Kuroda M">M Kuroda</name></author><author><name sortKey="Ohta, T" uniqKey="Ohta T">T Ohta</name></author><author><name sortKey="Uchiyama, I" uniqKey="Uchiyama I">I Uchiyama</name></author><author><name sortKey="Baba, T" uniqKey="Baba T">T Baba</name></author><author><name sortKey="Yuzawa, H" uniqKey="Yuzawa H">H Yuzawa</name></author><author><name sortKey="Kobayashi, I" uniqKey="Kobayashi I">I Kobayashi</name></author><author><name sortKey="Cui, L" uniqKey="Cui L">L Cui</name></author><author><name sortKey="Oguchi, A" uniqKey="Oguchi A">A Oguchi</name></author><author><name sortKey="Aoki, K" uniqKey="Aoki K">K Aoki</name></author><author><name sortKey="Nagai, Y" uniqKey="Nagai Y">Y Nagai</name></author><author><name sortKey="Lian, J" uniqKey="Lian J">J Lian</name></author><author><name sortKey="Ito, T" uniqKey="Ito T">T Ito</name></author><author><name sortKey="Kanamori, M" uniqKey="Kanamori M">M Kanamori</name></author><author><name sortKey="Matsumaru, H" uniqKey="Matsumaru H">H Matsumaru</name></author><author><name sortKey="Maruyama, A" uniqKey="Maruyama A">A Maruyama</name></author><author><name sortKey="Murakami, H" uniqKey="Murakami H">H Murakami</name></author><author><name sortKey="Hosoyama, A" uniqKey="Hosoyama A">A Hosoyama</name></author><author><name sortKey="Mizutani Ui, Y" uniqKey="Mizutani Ui Y">Y Mizutani-Ui</name></author><author><name sortKey="Takahashi, Nk" uniqKey="Takahashi N">NK Takahashi</name></author><author><name sortKey="Sawano, T" uniqKey="Sawano T">T Sawano</name></author><author><name sortKey="Inoue, R" uniqKey="Inoue R">R Inoue</name></author><author><name sortKey="Kaito, C" uniqKey="Kaito C">C Kaito</name></author><author><name sortKey="Sekimizu, K" uniqKey="Sekimizu K">K Sekimizu</name></author><author><name sortKey="Hirakawa, H" uniqKey="Hirakawa H">H Hirakawa</name></author><author><name sortKey="Kuhara, S" uniqKey="Kuhara S">S Kuhara</name></author><author><name sortKey="Goto, S" uniqKey="Goto S">S Goto</name></author><author><name sortKey="Yabuzaki, J" uniqKey="Yabuzaki J">J Yabuzaki</name></author><author><name sortKey="Kanehisa, M" uniqKey="Kanehisa M">M Kanehisa</name></author><author><name sortKey="Yamashita, A" uniqKey="Yamashita A">A Yamashita</name></author><author><name sortKey="Oshima, K" uniqKey="Oshima K">K Oshima</name></author><author><name sortKey="Furuya, K" uniqKey="Furuya K">K Furuya</name></author><author><name sortKey="Yoshino, C" uniqKey="Yoshino C">C Yoshino</name></author><author><name sortKey="Shiba, T" uniqKey="Shiba T">T Shiba</name></author><author><name sortKey="Hattori, M" uniqKey="Hattori M">M Hattori</name></author><author><name sortKey="Ogasawara, N" uniqKey="Ogasawara N">N Ogasawara</name></author><author><name sortKey="Hayashi, H" uniqKey="Hayashi H">H Hayashi</name></author><author><name sortKey="Hiramatsu, K" uniqKey="Hiramatsu K">K Hiramatsu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soares, Mj" uniqKey="Soares M">MJ Soares</name></author><author><name sortKey="Teixeira, La" uniqKey="Teixeira L">LA Teixeira</name></author><author><name sortKey="Nunes, Mr" uniqKey="Nunes M">MR Nunes</name></author><author><name sortKey="Da Silva Carvalho, Mc" uniqKey="Da Silva Carvalho M">MC da Silva Carvalho</name></author><author><name sortKey="Ferreira Carvalho, Bt" uniqKey="Ferreira Carvalho B">BT Ferreira-Carvalho</name></author><author><name sortKey="Figueiredo, Am" uniqKey="Figueiredo A">AM Figueiredo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cury, Gg" uniqKey="Cury G">GG Cury</name></author><author><name sortKey="Mobilon, C" uniqKey="Mobilon C">C Mobilon</name></author><author><name sortKey="Stehling, Eg" uniqKey="Stehling E">EG Stehling</name></author><author><name sortKey="Lancellotti, M" uniqKey="Lancellotti M">M Lancellotti</name></author><author><name sortKey="Ramos Mde, C" uniqKey="Ramos Mde C">C Ramos Mde</name></author><author><name sortKey="Martinez, R" uniqKey="Martinez R">R Martinez</name></author><author><name sortKey="Brocchi, M" uniqKey="Brocchi M">M Brocchi</name></author><author><name sortKey="Silveira, Wd" uniqKey="Silveira W">WD Silveira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rampazo, Lgl" uniqKey="Rampazo L">LGL Rampazo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duran, N" uniqKey="Duran N">N Durán</name></author><author><name sortKey="Marcato, Pd" uniqKey="Marcato P">PD Marcato</name></author><author><name sortKey="Alves, Ol" uniqKey="Alves O">OL Alves</name></author><author><name sortKey="De Souza, Gih" uniqKey="De Souza G">GIH de Souza</name></author><author><name sortKey="Esposito, E" uniqKey="Esposito E">E Esposito</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Chin, Nx" uniqKey="Chin N">NX Chin</name></author><author><name sortKey="Weitzman, I" uniqKey="Weitzman I">I Weitzman</name></author><author><name sortKey="Della Lata, P" uniqKey="Della Lata P">P Della-Lata</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hafidh, Rr" uniqKey="Hafidh R">RR Hafidh</name></author><author><name sortKey="Abdulamir, As" uniqKey="Abdulamir A">AS Abdulamir</name></author><author><name sortKey="Vern, Ls" uniqKey="Vern L">LS Vern</name></author><author><name sortKey="Abu Bakar, F" uniqKey="Abu Bakar F">F Abu Bakar</name></author><author><name sortKey="Abas, F" uniqKey="Abas F">F Abas</name></author><author><name sortKey="Jahanshiri, F" uniqKey="Jahanshiri F">F Jahanshiri</name></author><author><name sortKey="Sekawi, Z" uniqKey="Sekawi Z">Z Sekawi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chung, Py" uniqKey="Chung P">PY Chung</name></author><author><name sortKey="Navaratnam, P" uniqKey="Navaratnam P">P Navaratnam</name></author><author><name sortKey="Chung, Ly" uniqKey="Chung L">LY Chung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mandal, S" uniqKey="Mandal S">S Mandal</name></author><author><name sortKey="Manisha, D" uniqKey="Manisha D">D Manisha</name></author><author><name sortKey="Saha, K" uniqKey="Saha K">K Saha</name></author><author><name sortKey="Pal, Nk" uniqKey="Pal N">NK Pal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fukuda, D" uniqKey="Fukuda D">D Fukuda</name></author><author><name sortKey="Haines, As" uniqKey="Haines A">AS Haines</name></author><author><name sortKey="Song, Z" uniqKey="Song Z">Z Song</name></author><author><name sortKey="Murphy, Ac" uniqKey="Murphy A">AC Murphy</name></author><author><name sortKey="Hothersall, J" uniqKey="Hothersall J">J Hothersall</name></author><author><name sortKey="Stephens, Er" uniqKey="Stephens E">ER Stephens</name></author><author><name sortKey="Gurney, R" uniqKey="Gurney R">R Gurney</name></author><author><name sortKey="Cox, Rj" uniqKey="Cox R">RJ Cox</name></author><author><name sortKey="Crosby, J" uniqKey="Crosby J">J Crosby</name></author><author><name sortKey="Willis, Cl" uniqKey="Willis C">CL Willis</name></author><author><name sortKey="Simpson, Tj" uniqKey="Simpson T">TJ Simpson</name></author><author><name sortKey="Thomas, Cm" uniqKey="Thomas C">CM Thomas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laursen, Jb" uniqKey="Laursen J">JB Laursen</name></author><author><name sortKey="Nielsen, J" uniqKey="Nielsen J">J Nielsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mavrodi, Dv" uniqKey="Mavrodi D">DV Mavrodi</name></author><author><name sortKey="Blankenfeldt, W" uniqKey="Blankenfeldt W">W Blankenfeldt</name></author><author><name sortKey="Thomashow, Ls" uniqKey="Thomashow L">LS Thomashow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jayatilake, Gs" uniqKey="Jayatilake G">GS Jayatilake</name></author><author><name sortKey="Thornton, Mp" uniqKey="Thornton M">MP Thornton</name></author><author><name sortKey="Leonard, Ac" uniqKey="Leonard A">AC Leonard</name></author><author><name sortKey="Grimwade, Je" uniqKey="Grimwade J">JE Grimwade</name></author><author><name sortKey="Baker, Bj" uniqKey="Baker B">BJ Baker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, Ej" uniqKey="Choi E">EJ Choi</name></author><author><name sortKey="Kwon, Hc" uniqKey="Kwon H">HC Kwon</name></author><author><name sortKey="Ham, J" uniqKey="Ham J">J Ham</name></author><author><name sortKey="Yang, Ho" uniqKey="Yang H">HO Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shanmugaiah, Y" uniqKey="Shanmugaiah Y">Y Shanmugaiah</name></author><author><name sortKey="Mathivanan, N" uniqKey="Mathivanan N">N Mathivanan</name></author><author><name sortKey="Varghese, B" uniqKey="Varghese B">B Varghese</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chin A Woeng, Tfd" uniqKey="Chin A Woeng T">TFD Chin-A-Woeng</name></author><author><name sortKey="Bloemberg, Gv" uniqKey="Bloemberg G">GV Bloemberg</name></author><author><name sortKey="Lugtenberg, Bj" uniqKey="Lugtenberg B">BJ Lugtenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Konate, K" uniqKey="Konate K">K Konaté</name></author><author><name sortKey="Mavoungou, Jf" uniqKey="Mavoungou J">JF Mavoungou</name></author><author><name sortKey="Lepengue, An" uniqKey="Lepengue A">AN Lepengué</name></author><author><name sortKey="Aworet Samseny, Rrr" uniqKey="Aworet Samseny R">RRR Aworet-Samseny</name></author><author><name sortKey="Hilou, A" uniqKey="Hilou A">A Hilou</name></author><author><name sortKey="Souza, A" uniqKey="Souza A">A Souza</name></author><author><name sortKey="Dicko, Mh" uniqKey="Dicko M">MH Dicko</name></author><author><name sortKey="M Atchi, B" uniqKey="M Atchi B">B M’Batchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gribble, Gw" uniqKey="Gribble G">GW Gribble</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laus, G" uniqKey="Laus G">G Laus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jiang, Z" uniqKey="Jiang Z">Z Jiang</name></author><author><name sortKey="Boyd, Kg" uniqKey="Boyd K">KG Boyd</name></author><author><name sortKey="Mearns Spragg, A" uniqKey="Mearns Spragg A">A Mearns-Spragg</name></author><author><name sortKey="Adams, Dr" uniqKey="Adams D">DR Adams</name></author><author><name sortKey="Wright, Pc" uniqKey="Wright P">PC Wright</name></author><author><name sortKey="Burgess, Jg" uniqKey="Burgess J">JG Burgess</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article" xml:lang="en"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Clin Microbiol Antimicrob</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Clin. Microbiol. Antimicrob</journal-id><journal-title-group><journal-title>Annals of Clinical Microbiology and Antimicrobials</journal-title></journal-title-group><issn pub-type="epub">1476-0711</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23773484</article-id><article-id pub-id-type="pmc">3695862</article-id><article-id pub-id-type="publisher-id">1476-0711-12-12</article-id><article-id pub-id-type="doi">10.1186/1476-0711-12-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Antibacterial activity of extracellular compounds produced by a <italic>Pseudomonas</italic> strain against methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) strains</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Cardozo</surname><given-names>Viviane F</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vicardozo@yahoo.com.br</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Oliveira</surname><given-names>Admilton G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>admilton.oliveira@gmail.com</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A3"><name><surname>Nishio</surname><given-names>Erick K</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>erick.nishio@yahoo.com</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A4"><name><surname>Perugini</surname><given-names>Marcia RE</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>marciaperugini@hotmail.com</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A5"><name><surname>Andrade</surname><given-names>Célia GTJ</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>cgtardeli@uel.br</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A6"><name><surname>Silveira</surname><given-names>Wanderley D</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>wds@unicamp.br</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A7"><name><surname>Durán</surname><given-names>Nelson</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>duran@iqm.unicamp.br</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A8"><name><surname>Andrade</surname><given-names>Galdino</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>andradeg@uel.br</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A9"><name><surname>Kobayashi</surname><given-names>Renata KT</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kobayashirkt@uel.br</email></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="A10"><name><surname>Nakazato</surname><given-names>Gerson</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gersonakazato@yahoo.com.br</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Microbiology, Biology Sciences Center, University of Londrina State, Londrina, PR CP 86005-990, Brazil</aff><aff id="I2"><label>2</label>Department of Pathology, Clinical Analysis and Toxicological, University of Londrina State, Londrina, PR CP 86038-440, Brazil</aff><aff id="I3"><label>3</label>Department of General Biology, University of Londrina State, Londrina, PR CP 86051-990, Brazil</aff><aff id="I4"><label>4</label>Department of Genetics, Evolution and Bioagent, Biology Institute, Campinas State University (UNICAMP), Campinas, SP CP 13083-970, Brazil</aff><aff id="I5"><label>5</label>Department of Physical Chemistry, Chemistry Institute Campinas State University (UNICAMP), Campinas, SP CP 13083-970, Brazil</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>17</day><month>6</month><year>2013</year></pub-date><volume>12</volume><fpage>12</fpage><lpage>12</lpage><history><date date-type="received"><day>1</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>8</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Cardozo et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cardozo et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.ann-clinmicrob.com/content/12/1/12"></self-uri><abstract><sec><title>Background</title><p>The emergence of multidrug-resistant bacteria is a world health problem. <italic>Staphylococcus aureus,</italic> including methicillin-resistant <italic>S. aureus</italic> (MRSA) strains, is one of the most important human pathogens associated with hospital and community-acquired infections. The aim of this work was to evaluate the antibacterial activity of a <italic>Pseudomonas aeruginosa</italic>-derived compound against MRSA strains.</p></sec><sec><title>Methods</title><p>Thirty clinical MRSA strains were isolated, and three standard MRSA strains were evaluated. The extracellular compounds were purified by vacuum liquid chromatography. Evaluation of antibacterial activity was performed by agar diffusion technique, determination of the minimal inhibitory concentration, curve of growth and viability and scanning electron microscopy. Interaction of an extracellular compound with silver nanoparticle was studied to evaluate antibacterial effect.</p></sec><sec><title>Results</title><p>The F3 (ethyl acetate) and F3d (dichloromethane- ethyl acetate) fractions demonstrated antibacterial activity against the MRSA strains. Phenazine-1-carboxamide was identified and purified from the F3d fraction and demonstrated slight antibacterial activity against MRSA, and synergic effect when combined with silver nanoparticles produced by <italic>Fusarium oxysporum</italic>. Organohalogen compound was purified from this fraction showing high antibacterial effect. Using scanning electron microscopy, we show that the F3d fraction caused morphological changes to the cell wall of the MRSA strains.</p></sec><sec><title>Conclusions</title><p>These results suggest that <italic>P. aeruginosa</italic>-produced compounds such as phenazines have inhibitory effects against MRSA and may be a good alternative treatment to control infections caused by MRSA.</p></sec></abstract><kwd-group><kwd>Antibacterial activity</kwd><kwd>Methicillin-resistant</kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd><kwd><italic>Staphylococcus aureus</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The emergence of multidrug-resistant bacteria is a world health problem [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. <italic>Staphylococcus aureus</italic> is one of the most important human pathogens associated with hospital and community-acquired infections. Over the last few decades, the number and proportion of methicillin-resistant <italic>S. aureus</italic> (MRSA) infections in different countries has increased due to the rise of epidemics in humans [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>] and other animals, such as dogs, cats, cattle, pigs and exotic species [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. In Brazil, according to data obtained from the first five years of the SENTRY Antimicrobial Surveillance Program, MRSA strains were among the most prevalent pathogens and contributed to 56% of the nosocomial and community infections [<xref ref-type="bibr" rid="B8">8</xref>]. One of the major global clones is the MRSA Brazilian epidemic clone (BEC), a hospital-acquired MRSA strain. Isolates of this strain are typically resistant to multiple antimicrobials [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>The expense incurred to control MRSA may be considerable; however, several economic evaluations have indicated that MRSA control programs are cost-effective in terms of reducing the costs of MRSA infections. In a study comparing two neonatal ICUs, the cost of instituting control measures in a stepwise, delayed approach was US$ 49–69 million (€ 38–52 million), while the cost of introducing effective and immediate measures was US$ 1.3 million (€ 1 million) [<xref ref-type="bibr" rid="B10">10</xref>]. Another study calculated that the total cost per case of bacteremia that was caused by an antibiotic-resistant strain, including MRSA (50% of the cases), was US$ 88,445 [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>The health risks associated with MRSA infections, including its potential to produce invasive infections, particularly in vulnerable patients, and its resistance to multiple antibiotics, warrant the implementation of monitoring programs to control its dissemination. There is a considerable epidemiological interest in tracking strains to gain a more complete picture of the distribution of strains in the population and the dynamics of clonal spread [<xref ref-type="bibr" rid="B12">12</xref>]. For years, vancomycin has been used as the drug of choice to treat MRSA infections and was recommended by clinical guidelines; however, the emergence of the vancomycin-resistant <italic>S. aureus</italic> (VRSA) and vancomycin-intermediate <italic>S. aureus</italic> (VISA) has made antibacterial therapy difficult. Therefore, new chemotherapeutic compounds to treat and control infections by these microorganisms have been broadly studied and developed [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>Recently, some natural antibacterial agents, such <italic>Quercus dilatata</italic>, <italic>Hylomecon hylomeconoides, Eleutherine Americana</italic>, <italic>Chelidonium majus</italic> Linn. (<italic>Papaveraceae</italic>) and <italic>Tabebuia avellanedae</italic> compounds, have been tested against MRSA [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B18">18</xref>].</p><p>The ability of antibacterial compounds obtained from other bacteria to inhibit methicillin-sensitive <italic>S. aureus</italic> (MSSA) and MRSA has also been tested [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Other bacterial compounds known to have antibacterial activity have not been tested against MRSA. We have tested an extracellular compound derived from <italic>Pseudomonas aeruginosa</italic> that has previously been shown to have antibacterial effects against <italic>Xanthomonas citri</italic> pv. Citri, which causes citrus cancer lesions [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>The aim of this work was to evaluate the antibacterial activity of a compound from <italic>P. aeruginosa</italic> against MRSA strains.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Bacteria strains</title><p>Thirty MRSA strains from bacteria collection of the hospital of Londrina State University, and isolated in 2011, Londrina-PR, Brazil. The MRSA strains were isolated from blood, urine, trachea and secretion cultures. Three standard MRSA strains were also used in this work. The strains MRSA N315 [<xref ref-type="bibr" rid="B23">23</xref>], BEC9393 [<xref ref-type="bibr" rid="B24">24</xref>] and rib1 [<xref ref-type="bibr" rid="B25">25</xref>] were provided by Dr. Elsa Masae Mamizuka (Universidade de São Paulo, São Paulo-SP, Brazil), Dr. Agnes Marie Sá Figueiredo (Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil), and Dr. Wanderley Dias da Silveira (Universidade Estadual de Campinas, Campinas-SP, Brazil), respectively. All strains were stored at - 80°C in stocks containing glycerol (2.5 M).</p></sec><sec><title>Extracellular compounds from <italic>Pseudomonas aeruginosa</italic></title><p>The extracellular compounds were provided by Dr. Galdino Andrade from the Laboratory of Microbial Ecology (Londrina State University, Londrina-PR, Brazil). The method of production has been patented (Patent, 2008#PI0803350-1; <ext-link ext-link-type="uri" xlink:href="http://www.inpi.gov.br">http://www.inpi.gov.br</ext-link>). These antibacterial compounds were obtained from the <italic>P. aeruginosa</italic> LV strain that was isolated from an old citrus canker lesion on the leaves of orange (<italic>Citrus sinensis</italic> cv. Valence) plants and collected in Astorga, Brazil [<xref ref-type="bibr" rid="B26">26</xref>]. The production and purification of these compounds by vacuum liquid chromatography (VLC) were performed as described by Oliveira and collaborators (2011) [<xref ref-type="bibr" rid="B22">22</xref>]. The culture supernatants were treated with dichloromethane 1:1 (v:v). The dichloromethane phase (DP) was fractionated using the mobile phase (v/v): hexane (100:F1); dichloromethane (100; F2); ethyl acetate (100; F3); methanol (100; F4); methanol–water (1:1; F5); and water (100; F6). Fractionation was performed again using the following phase (v/v): hexane (100; F3a); hexane-dichloromethane (1:1; F3b); dichloromethane (100; F3c); dichloromethane- ethyl acetate (1:1; F3d); ethyl acetate (100; F3e); ethyl acetate-methanol (1:1; F3f); methanol (100; F3g); methanol–water (1:1; F3h); and water (100; F3i). In this study, the F3 and F3d fractions were used to evaluate the antibiosis effect. All reagents were purchased from Sigma-Aldrich, USA.</p></sec><sec><title>Silver nanoparticles from <italic>Fusarium oxysporum</italic></title><p>The silver nanoparticles were obtained following the method of Durán and collaborators (2005) [<xref ref-type="bibr" rid="B27">27</xref>]. After the growth of <italic>F. oxysporum</italic> culture, 10 g of the biomass was added in 100 ml of distilled water. After incubation of 72 h at 28°C, the solution components were separated by filtration, and AgNO3 at concentration of 10<sup>-3</sup>M was added and the system was kept for several hours and then the absorbance at 420 nm that corresponds to the plasmon resonance value was determined. The silver nanoparticles were characterized by Transmission Electron Microscopy (TEM) (Carl Zeiss CEM-902, 80 KeV).</p></sec><sec><title>Cytotoxicity assay</title><p>The LLC-MK<sub>2</sub> cell line was cultured in a 96-well culture plate at a density of 2.5 × 10<sup>5</sup> cells/well and incubated for 24 h. When the cells were confluent, the non-adherent cells were removed by washing with sterile 0.01 M phosphate buffered saline (PBS). The medium containing different concentrations of F3d (1 to 2000 <italic>μ</italic>g/ml) was added to each well containing the cells, and the plates were incubated for 72 h. For the controls, the cells were cultured in the growth medium alone or in the presence of 1% dimethyl sulfoxide (DMSO). Cell viability was determined by the dimethylthiazol diphenyl tetrazolium bromide (MTT, Sigma-Aldrich, USA) method, according to the manufacturer’s recommendation. The concentration of the compounds needed to inhibit the viability of cells by 50% (IC<sub>50</sub>) was determined by regression analysis. The 50% cytotoxic concentration (CC<sub>50/72h</sub>) and the selectivity index (SI) were calculated using the equation: SI = CC<sub>50</sub>/IC<sub>50</sub>.</p></sec><sec><title>Evaluation of the antibiosis effect by the agar diffusion technique</title><p>The experiment was carried out with three replicates of two fractions obtained from the dichloromethane phase at two concentrations (100 and 500 μg/ml). The negative control was the dichloromethane phase alone (compound solvent). The antibiotic effect of the fraction on the MRSA strains was evaluated on Mueller Hinton agar plates (Difco, USA). MRSA suspensions of 10<sup>8</sup> colony-forming units (CFU)/ml were grown to log phase, and the diffusion disks were treated with the antibiotic compounds. The plates were incubated at 35°C for 24 h, and the size of the inhibition halos diameter was evaluated (mm). The experiment was repeated three times, and the antibiosis effect was determined by measuring the size of inhibited halos formed around the wells.</p></sec><sec><title>Determination of the minimal inhibitory concentration (MIC)</title><p>The minimal inhibitory concentrations (MICs) were determined by micro-dilution assays in 96-well plates, as suggested by the CLSI (2011) [<xref ref-type="bibr" rid="B28">28</xref>]. In brief, single colonies of bacterial cultures grown in Mueller-Hinton agar (Sigma-Aldrich, USA) media were diluted in saline solution and adjusted to 0.5 on the MacFarland scale, which corresponds to 1.5 × 10<sup>8</sup> CFU/ml. Then, the bacterial suspensions were diluted in Mueller-Hinton broth (Difco, USA) and plated in 96-well plates at a density of 5.0 × 10<sup>5</sup> CFU/well. Finally, different concentrations of the analyzed antibiotics and compounds were added to each well to determine the MIC values. As negative control, DMSO (Sigma-Aldrich, USA) alone was added in equal concentrations as the ones used to solubilize the antibiotic compounds. The plates were incubated at 37°C for 18 h, and then the optical density values at 600 nm were determined using a Bio-Rad Microplate Reader model 3550.</p></sec><sec><title>Curve of growth and viability</title><p>To quantify the effect of compounds on the bacterial growth, a time-response growth curve was obtained in the presence of these antimicrobials. In brief, a single colony forming unit (CFU) of each MRSA strain was diluted in Mueller-Hinton broth and grown for 18 hours at 37°C with constant stirring at 200 rpm. Then, each culture was adjusted to 0.5 index in MacFarland scale and inoculated at a cell density of 10<sup>6</sup> CFU/ml in 2 ml of Mueller-Hinton broth. For each strain culture was divided in two new cultures of 1 ml each. One culture received the antimicrobial compound and other received only the solvent (control). The bacterial cultures were then incubated at 37°C with constant stirring (200 rpm). In different times, an aliquot of the broth was collected, serial diluted in saline solution, plated on Mueller-Hinton agar media and grown for 18 h at 37°C in order to determine the total CFU of each culture.</p></sec><sec><title>Drug interaction studies</title><p>To evaluate the antibacterial effects and interactions of phenazine-1-carboxamide combined with silver nanoparticle produced by <italic>Fusarium oxyporum</italic> against MRSA, assays of microdilution in double-antimicrobial gradient were used. Briefly, the MIC values for phenazine and silver nanoparticle used alone were determined, and several concentrations of phenazine were combined with different concentrations of the silver nanoparticle. The MIC of the combination, which is the lowest concentration of phenazine that, when combined with the lowest concentration of silver nanoparticle, were determined. To evaluate the interaction between both antimicrobials, the fractionated inhibitory concentration (FIC) index was used as described by Chin and collaborators (1998) [<xref ref-type="bibr" rid="B29">29</xref>]:</p><p><disp-formula><mml:math id="M1" name="1476-0711-12-12-i1" overflow="scroll"><mml:mrow><mml:mi mathvariant="normal">FIC</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">MIC</mml:mi><mml:mfenced open="(" close=")"><mml:mi mathvariant="normal">Pc</mml:mi></mml:mfenced><mml:mo stretchy="true">/</mml:mo><mml:mi mathvariant="normal">MIC</mml:mi><mml:mfenced open="(" close=")"><mml:mi mathvariant="normal">Pa</mml:mi></mml:mfenced><mml:mo>+</mml:mo><mml:mi mathvariant="normal">MIC</mml:mi><mml:mfenced open="(" close=")"><mml:mi mathvariant="normal">Sc</mml:mi></mml:mfenced><mml:mo stretchy="true">/</mml:mo><mml:mi mathvariant="normal">MIC</mml:mi><mml:mfenced open="(" close=")"><mml:mi mathvariant="normal">Sa</mml:mi></mml:mfenced></mml:mrow></mml:math></disp-formula></p><p>Where MIC(Pc) is the MIC of phenazine used combined with the silver nanoparticle, MIC(Pa) is the MIC of free phenzine used alone, MIC(Sc) is the MIC of the silver nanoparticle used combined with phenazine and MIC(Aa) is the MIC of the silver nanoparticle used alone. FIC indexes were interpreted as follows: FIC ≤ 0.5 = synergic interaction; 0.5 < FIC ≤ 1.0 = additive interaction; 1.0 < FIC ≤ 4.0 = no interaction; FIC > 4.0 = antagonist interaction.</p></sec><sec><title>Scanning Electron Microscopy (SEM)</title><p>For scanning electron microscopy (SEM), suspensions of the MRSA strains (10<sup>10</sup> CFU/ml) with and without the antibacterial compound (at about MIC) were spotted onto polylysine-coated glass slides. Each slide was then fixed by immersion in 1 ml of 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 12 h and then post-fixed in 1% OsO<sub>4</sub> for 2 h. The fixed samples were dehydrated in an ethanol gradient (70, 80, 90 and 100˚GL) and then were critical point dried in CO<sub>2</sub> (BALTEC CPD 030 Critical Point Dryer). Finally, the slides were taped onto stubs, coated with gold (BALTEC SDC 050 Sputter Coater) and observed under a FEI Quanta 200 SEM. All reagents were purchased from Sigma-Aldrich, USA.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Extracellular compound</title><p>Phenazine-1-carboxamide and organohalogen were identified from the F3d fraction. These compounds were extracted, purified, and evaluated for antibiosis effects. The organohalogen specific structure does not identified yet.</p></sec><sec><title>Cytotoxicity assay</title><p>It was not possible to determine the 50% cytotoxic concentration of the F3d fraction on LLC-MK<sub>2</sub> cells because even with the highest concentration tested (2000 <italic>μ</italic>g/ml), 84% of the cells were viable, according to the MTT assay.</p></sec><sec><title>Diffusion disc-mediated antibiotic treatments against MRSA strains</title><p>As an initial screen to evaluate the antimicrobial activity again MRSA, we measured the diameters of the zone of inhibition generated by the F3 fraction against the MRSA standard and clinical isolates (Table <xref ref-type="table" rid="T1">1</xref>). There was no difference in the size of the zones for the MRSA standards; however, there was some variation in the zones for the clinical isolates. Discs treated with only dichloromethane (solvent) were also tested and showed no inhibition zones. Discs were impregnated with 25 μg of organohalogen from F3d fraction showed high zones of inhibition for MRSA strain N315 (Table <xref ref-type="table" rid="T1">1</xref>). The strains MRSA N315, BEC9393 and rib1 showed resistance for erythromycin, gentamicin, penicillin and ampicillin antimicrobials (data not shown).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The MIC and diameters of the zones of inhibition (mm) generated by the F3 fraction diffusion discs against standard MRSA strains grown on agar</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col><col align="left"></col></colgroup><thead valign="top"><tr><th align="left"><bold>MRSA strains</bold></th><th align="left"><bold>F3 disk (500 μg) zone (mm)</bold></th><th align="left"><bold>F3 disk (100 μg) zone (mm)</bold></th><th align="left"><bold>Organohalogen (25 μg) zone (mm)</bold></th><th align="left"><bold>MIC F3 (μg/ml)</bold></th><th align="left"><bold>MIC F3d (μg/ml)</bold></th><th align="left"><bold>MIC phenazine (μg/ml)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">N315<hr></hr></td><td align="left" valign="bottom">22<hr></hr></td><td align="left" valign="bottom">12<hr></hr></td><td align="left" valign="bottom">28<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">250<hr></hr></td></tr><tr><td align="left" valign="bottom">BEC9393<hr></hr></td><td align="left" valign="bottom">23<hr></hr></td><td align="left" valign="bottom">12<hr></hr></td><td align="left" valign="bottom">NT<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">NT<hr></hr></td></tr><tr><td align="left" valign="bottom">Rib1<hr></hr></td><td align="left" valign="bottom">22<hr></hr></td><td align="left" valign="bottom">12<hr></hr></td><td align="left" valign="bottom">NT<hr></hr></td><td align="left" valign="bottom">125<hr></hr></td><td align="left" valign="bottom">NT<hr></hr></td><td align="left" valign="bottom">NT<hr></hr></td></tr><tr><td align="left">MRSA clinical</td><td align="left">16 - 27</td><td align="left">08 - 15</td><td align="left">NT</td><td align="left">NT</td><td align="left">NT</td><td align="left">NT</td></tr></tbody></table><table-wrap-foot><p><italic>NT</italic> not tested.</p><p><italic>MIC</italic> Minimal Inhibitory Concentration.</p><p><italic>MRSA</italic> Methicillin-resistant <italic>Staphylococcus aureus.</italic></p></table-wrap-foot></table-wrap></sec><sec><title>Minimal Inhibitory Concentration (MIC)</title><p>The MICs of the F3 fraction for MRSA strains (N315, BEC9393 and Rib1) were in the range of 125 μg/ml. The MIC for the more purified F3d fraction was equal to the F3 fraction. The MIC for phenazine-1-carboxamide was 250 μg/ml for the MRSA strain N315 (Table <xref ref-type="table" rid="T1">1</xref>). These compounds do not have breakpoints because they are new antibiotics (Table <xref ref-type="table" rid="T1">1</xref>). The MRSA strain N315 was further selected for curve of growth and viability tests and scanning electron microscopy.</p></sec><sec><title>Curve of growth and viability</title><p>At 125 μg/ml, the F3 fraction significantly reduced the number of CFUs over the incubation time (data not shown). A similar effect occurred with the F3d fraction (200 μg/ml) (Figure <xref ref-type="fig" rid="F1">1</xref>) and with phenazine-1-carboxamide (250 μg/ml) (Figure <xref ref-type="fig" rid="F2">2</xref>). The number of CFUs after 7 h of incubation with the F3d fraction (200 μg/ml) and phenazine-1-carboxamide (250 μg/ml) was about 10,000-fold lower than the control (without treatment) (Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>). After 24 h of incubation with the F3d fraction, all the bacteria were eliminated (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Time-kill curves of </bold><bold><italic>Staphylococcus aureus </italic></bold><bold>N315 strain exposed to F3d fraction Notes - straight line: without antibiotic treatment; dash line: F3d treatment (200 μg/ml).</bold></p></caption><graphic xlink:href="1476-0711-12-12-1"></graphic></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Time-kill curves of </bold><bold><italic>Staphylococcus aureus </italic></bold><bold>N315 strain exposed to phenazine-1-carboxamide.</bold> Notes - dash line: control; straight line: phenazine treatment (125 μg/ml); large line: phenazine treatment (250 μg/ml).</p></caption><graphic xlink:href="1476-0711-12-12-2"></graphic></fig></sec><sec><title>Drug interaction studies</title><p>Phenazine-1-carboxamide was combined with silver nanoparticle for evaluation synergic effect against MRSA N315 strain. The MICs for phenazine and nanoparticle alone were 250 μg/ml and 125 μM respectively. The MICs for these compounds combined were 7.81 μg/ml and 31.25 μM, showing the FIC at 0.281 (synergic interaction).</p></sec><sec><title>Scanning Electron Microscopy (SEM)</title><p>The SEM analysis showed that at a low concentration of F3d, morphological changes in the bacteria could be observed within a few hours (Figure <xref ref-type="fig" rid="F3">3</xref>C and <xref ref-type="fig" rid="F3">3</xref>D). No morphological changes were observed after 30 min of incubation with F3d, but the number of cells was reduced (Figure <xref ref-type="fig" rid="F3">3</xref>B). After 2 h, we observed the cell wall sinking into the bacterial body (Figure <xref ref-type="fig" rid="F3">3</xref>C). Some cells were deformed after 4 h (Figure <xref ref-type="fig" rid="F3">3</xref>D). In contrast, the untreated cells (treated only with solvent) appeared intact, and the cell wall was not deformed (Figure <xref ref-type="fig" rid="F3">3</xref>A). This assay was performed with 100 μg/ml of the F3d fraction.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Scanning electron microscopy images of the antibacterial effect of the F3d fraction (200 μg/ml) against the MRSA N315 strain at different times. A</bold>: negative control (2 h without antibiotic); <bold>B</bold>: F3d (30 min); <bold>C</bold>: F3d (2 h); <bold>D</bold>: F3d (4 h). When the bacteria were incubated with the F3d fraction for 2 and 4 h, morphological alterations were observed. No morphological cellular alterations were observed with 30 min incubation.</p></caption><graphic xlink:href="1476-0711-12-12-3"></graphic></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The continuous selection of bacteria that are resistant against a wide range of antibiotics necessitates the discovery of novel unconventional sources of antibiotics, mainly in hospitals. Methicillin-resistant <italic>S. aureus</italic> (MRSA), <italic>Escherichia coli</italic> O157:H7, <italic>Mycobacterium tuberculosis</italic> and <italic>P. aeruginosa</italic> have been considered some of the most virulent microorganisms for the human population.</p><p>Notably, MRSA and VISA strains have a thickened cell wall that is believed to deplete the vancomycin available to kill the bacterium; this mechanism of resistance would significantly impact the near future prospects of the current anti-MRSA therapies. The methanol crude extract of <italic>Brassica oleracea</italic> L. (red cabbage) was investigated for possible antimicrobial activity. The anti-MRSA activity of the red cabbage extract and its underlying mechanism of action appear to be novel and different from other known antibiotics. Accordingly, the discovery of natural, effective, and cheap drugs against this resistant bacterium may be a breakthrough solution for this worldwide problem [<xref ref-type="bibr" rid="B30">30</xref>].</p><p>The pentacyclic triterpenoids α-amyrin, betulinic acid and betulinaldehyde and other related triterpenes, such as imberbic acid, oleanolic acid (oleanic acid), ursolic acid, ulsolic acid, rotundic acid and zeylasteral, have been reported to possess antimicrobial activity [<xref ref-type="bibr" rid="B31">31</xref>]. Preliminary studies have shown that the pentacyclic triterpenoids have weak antibacterial activity against the reference strains of methicillin-resistant (ATCC 43300) [<xref ref-type="bibr" rid="B31">31</xref>]. All three triterpenoids exhibited a bacteriostatic effect against the reference strains of <italic>S. aureus</italic> at the concentrations tested. Synergism against the two reference strains was reproducibly observed between the three compounds and cell wall inhibitors of the β-lactam and glycopeptide classes. The best synergistic combination was betulinic acid and methicillin [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>The bactericidal effect of the ethanolic extracts of the stem bark of cinnamon (<italic>Cinnamomum zeylanicum</italic>; CIN), the flower bud and stalk of clove (<italic>Syzygium aromaticum</italic>, CLV) and the seed of cumin (<italic>Cuminum cyminum</italic>, CMN) were tested on MRSA. In decreasing order, the antibacterial activities for the spices were <italic>C. zeylanicum</italic> > <italic>S. aromaticum</italic> > <italic>C. cyminum</italic>. All three spices were excellent bactericidal agents and are potential anti-MRSA agents [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>Thiomarinols, produced by marine bacteria belonging to the genus <italic>Pseudoalteromonas</italic>, are hybrids of two independently active species: the pseudomonic acid mixture, mupirocin, which is used clinically against MRSA, and the pyrrothine core of holomycin. Thiomarinols are a novel family of natural compounds with potent antimicrobial activity. Understanding how complex antibiotics are synthesized by their producer bacteria to create new families of bioactive compounds [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Recently, the violacein produced by <italic>Chromobacterium violaceum</italic> has an inhibitory effect against <italic>S. aureus</italic> isolated from bovine mastitis and displays synergism with penicillin [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>The F3 compound studied in this work is effective against <italic>Xanthomonas citri</italic> pv. Citri, which causes citrus canker lesions [<xref ref-type="bibr" rid="B22">22</xref>]. The F3 fraction was initially tested against other bacteria such as <italic>Staphylococcus</italic> spp., <italic>Enterococcus</italic> spp., <italic>Klebsiella pneumoniae</italic>, <italic>E. coli</italic>, <italic>P. aeruginosa</italic> and <italic>Salmonella enterica</italic> serovar Typhimurium and Enteritidis. The initial results demonstrated that the compound was effective against <italic>S. aureus</italic>, <italic>S. epidermidis</italic>, <italic>Enterococcus faecium</italic> and <italic>K. pneumoniae</italic> (data not shown). Among these bacteria, <italic>Staphylococcus</italic> spp. had the largest inhibition zones in the diffusion disc test.</p><p>Because many hospital infections involve MRSA, we evaluated the effect of the F3 fraction standard and clinical strains on MRSA.</p><p>The zones of inhibition in the diffusion disc test and the MICs for the F3 fraction were similar among the standard and clinical MRSA and MSSA strains. The MICs for MRSA were higher than for <italic>X. citri</italic>; however, these results are very significant and important for therapies used to treat diseases caused by these strains. For the experiments discussed, the F3d fraction was purified from the F3 fraction.</p><p>When we evaluated the F3d effect, we found that within a few hours (2 to 5 h), the number of CFUs decreased significantly, indicating that this compound acts rapidly on these strains. In our <italic>in vitro</italic> tests, the F3d fraction had a bactericidal effect at 200 μg/ml.</p><p>By electron microscopy, we observed cellular morphological alterations within a few hours of incubation with lower concentrations of the F3d fraction. The alterations were similar to the effects on <italic>X. citri</italic>[<xref ref-type="bibr" rid="B22">22</xref>]. In addition to reducing of the number of CFUs, we observed deformation and sinking of the bacterial cell wall (Figure <xref ref-type="fig" rid="F3">3</xref>C and <xref ref-type="fig" rid="F3">3</xref>D).</p><p>The results of the cytotoxicity assay demonstrated that the F3d compound does not have cytopathic effects and is not cytotoxic to LLC-MK<sub>2</sub> cells, suggesting low toxicity to the host. Thus, this compound could be used in patients, without side-effects.</p><p>Phenazines are natural products found in <italic>Pseudomonas</italic> spp., <italic>Streptomyces</italic> and a few other genera from soil or marine habitats. Phenazines are large family of colorful, nitrogen-containing tricyclic molecules with antibiotic, antitumor, and antiparasitic activities [<xref ref-type="bibr" rid="B34">34</xref>]. Phenazines isolated from <italic>Pseudomonas</italic> species (e.g. <italic>aeruginosa</italic>, <italic>aureofaciens</italic>, <italic>fluorescens</italic> and <italic>cepacia</italic>) are mostly simple hydroxyl- and carboxyl-substituted structures. Pyocyanin (5-N-methyl-1-hydroxyphenazine), phenazine-1-carboxylic (PCA) and phenazine-1-carboxamide (Figure <xref ref-type="fig" rid="F4">4</xref>) are among the phenazines produced by Pseudomonads, mainly rhizosphere isolates [<xref ref-type="bibr" rid="B35">35</xref>]. In our study, we identified phenazine-1-carboxamide (Figure <xref ref-type="fig" rid="F4">4</xref>) in the F3d fraction. This substance was effective against <italic>S. aureus</italic>, including the MRSA strain N315. The MIC (250 μg/ml) of phenazine for these strains was greater than for the F3 and F3d fraction (125 μg/ml) (Table <xref ref-type="table" rid="T1">1</xref>). In other words, the phenazine was less effective than the F3 and F3d compounds. The growth and viability curve with phenazine was similar to F3 and F3d treatment (Figure <xref ref-type="fig" rid="F2">2</xref>). These results demonstrate that phenazine-1-carboxamide from the F3d fraction has a slight inhibitory effect on <italic>S. aureus</italic>, including MRSA. The higher MIC of phenazine suggests that the F3d fraction contains other inhibitory substances or synergistic compounds. Physiologically, phenazine physiological inhibits and controls nucleic acid and protein synthesis [<xref ref-type="bibr" rid="B34">34</xref>]. Therefore, the modes of action for phenazines may include interactions with DNA (intercalation or groove binding), topoisomerases, anti-oxidants or charge-transferring molecules [<xref ref-type="bibr" rid="B34">34</xref>].</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Chemical structure of phenazine-1-carboxamide.</p></caption><graphic xlink:href="1476-0711-12-12-4"></graphic></fig><p>Some studies have demonstrated that phenazine efficiently inhibits the growth of bacterial and fungi [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. There are no studies showing that phenazine-1-carboxamide has an antibacterial effect on MRSA. Another study has reported that phenazine has antimicrobial activity on major rice pathogens, such as <italic>Rhizoctonia solani</italic> and <italic>Xanthomonas oryzae</italic> pv. Oryzae [<xref ref-type="bibr" rid="B38">38</xref>]. Ecological investigations of the action and crucial role of phenazines have focused in suppressing fungal pathogens of plants such as <italic>Fusarium oxysporum</italic> and <italic>Gaeumannomyces graminis</italic>[<xref ref-type="bibr" rid="B39">39</xref>].</p><p>The combination of phenazine-1-carboxamide and silver nanoparticle produced by <italic>F. oxysporum</italic> showed synergic effect decreasing up to 32 times the MIC value of phenazine. Studies involving synergism have been very important for antibacterial therapy mainly for multiresistant bacteria. Some natural products have shown anti-staphylococcal activities weaker than others antibiotics, but synergic interactions may use different mechanism of action or pathways to demonstrate their antimicrobial effects, as resulting in the lowered MICs [<xref ref-type="bibr" rid="B40">40</xref>]. The combination of current antibiotics with plant-derived antibacterial agents has showed synergic effect against MRSA [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>An organohalogen compound also was identified from F3d fraction and showed high inhibitory activity against MRSA strain N315. The specific structure has not been identified, but future studies on this organohalogen will conducted. Like penicillin, morphine, vincristine, aspirin and other natural products, several natural organohalogens have important medicinal value [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. The 2,4-dibromophenol-6-chloro compound isolated from a marine filamentous bacterium, <italic>Pseudoalteromonas luteoviolacea</italic>, shows antibacterial activity against MRSA [<xref ref-type="bibr" rid="B43">43</xref>].</p><p>There are few effective antimicrobials against multiresistant bacteria including MRSA strains. These antimicrobials are often associated with high costs and serious side effects for the patients. Many different natural antimicrobials have been studied as an alternative to control these infections. Our study suggests that the use of a secondary metabolite from bacteria such as <italic>P. aeruginosa</italic> could be effective again MRSA strains that cause diseases in humans and other animals. This compound may be a good alternative to treat and control of infections caused by MRSA.</p></sec><sec><title>Competing interest</title><p>The authors declared that they have no competing interests.</p></sec><sec><title>Authors’ contributions</title><p>VC performed all experiments (master thesis). AO purified and provided phenazine-carboxamide. EN assisted synergism and electronic microscopy assays. MP provided MRSA clinical strains and involved in analysis of clinical aspects. CA supervised electronic microscopy. WS involved in drug interaction analysis. ND involved in silver nanoparticles. GA involved in compounds of <italic>Pseudomonas aeruginosa</italic> (F3 and F3d fractions). RK involved in antibacterial activity. GN involved in designing of the project, results analysis, and write up of the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgments</title><p>To the National Council of Scientific and Technological Development (CNPq), Araucária Foundation - Paraná State, and Coordination of Improvement of Higher Education Personnel (CAPES), who enabled the execution of this study. The authors thank Dr. Elsa Masae Mamizuka and Dr. Agnes Marie Sá Figueiredo for providing the standard strains.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Buke</surname><given-names>C</given-names></name><name><surname>Armand-Lefevre</surname><given-names>L</given-names></name><name><surname>Lolom</surname><given-names>I</given-names></name><name><surname>Guerinot</surname><given-names>W</given-names></name><name><surname>Deblangy</surname><given-names>C</given-names></name><name><surname>Ruimy</surname><given-names>R</given-names></name><name><surname>Andremont</surname><given-names>A</given-names></name><name><surname>Lucet</surname><given-names>JC</given-names></name><article-title>Epidemiology of multidrug-resistant bacteria in patients with long hospital stays</article-title><source>Infect Control Hosp Epidemiol</source><year>2007</year><volume>28</volume><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1086/522678</pub-id><pub-id pub-id-type="pmid">17926276</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Strateva</surname><given-names>T</given-names></name><name><surname>Ouzounova-Raykova</surname><given-names>V</given-names></name><name><surname>Markova</surname><given-names>B</given-names></name><name><surname>Todorova</surname><given-names>A</given-names></name><name><surname>Marteva-Proevska</surname><given-names>Y</given-names></name><name><surname>Mitov</surname><given-names>I</given-names></name><article-title>Problematic clinical isolates of <italic>Pseudomonas aeruginosa</italic> from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms</article-title><source>J Med Microbiol</source><year>2007</year><volume>56</volume><fpage>956</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.46986-0</pub-id><pub-id pub-id-type="pmid">17577062</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Stefani</surname><given-names>S</given-names></name><name><surname>Varaldo</surname><given-names>PE</given-names></name><article-title>Epidemiology of methicillin-resistant staphylococci in Europe</article-title><source>Clin Microbiol Infect</source><year>2003</year><volume>9</volume><fpage>1179</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2003.00698.x</pub-id><pub-id pub-id-type="pmid">14686982</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Rodríguez-Noriega</surname><given-names>E</given-names></name><name><surname>Seas</surname><given-names>C</given-names></name><name><surname>Guzmán-Blanco</surname><given-names>M</given-names></name><name><surname>Mejía</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Bavestrello</surname><given-names>L</given-names></name><name><surname>Zurita</surname><given-names>J</given-names></name><name><surname>Labarca</surname><given-names>J</given-names></name><name><surname>Luna</surname><given-names>CM</given-names></name><name><surname>Salles</surname><given-names>MJ</given-names></name><name><surname>Gotuzzo</surname><given-names>E</given-names></name><article-title>Evolution of methicillin-resistant <italic>Staphylococcus aureus</italic> clones in Latin America</article-title><source>Int J Infect Dis</source><year>2010</year><volume>14</volume><fpage>e560</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2009.08.018</pub-id><pub-id pub-id-type="pmid">20047848</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>AS</given-names></name><name><surname>Huttner</surname><given-names>B</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><article-title>Control of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Infect Dis Clin North Am</source><year>2011</year><volume>25</volume><fpage>155</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2010.11.002</pub-id><pub-id pub-id-type="pmid">21315999</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Weese</surname><given-names>JS</given-names></name><article-title>Methicillin-resistant <italic>Staphylococcus aureus</italic> in animals</article-title><source>ILAR J</source><year>2010</year><volume>51</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1093/ilar.51.3.233</pub-id><pub-id pub-id-type="pmid">21131724</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>TC</given-names></name><name><surname>Pearson</surname><given-names>N</given-names></name><article-title>The emergence of <italic>Staphylococcus aureus</italic> ST398</article-title><source>Vector Borne Zoonotic Dis</source><year>2011</year><volume>11</volume><fpage>327</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1089/vbz.2010.0072</pub-id><pub-id pub-id-type="pmid">20925523</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Sader</surname><given-names>HS</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name><name><surname>Gales</surname><given-names>AC</given-names></name><name><surname>Silva</surname><given-names>JB</given-names></name><name><surname>Pignatari</surname><given-names>AC</given-names></name><collab>SENTRY Participants Group (Latin America)</collab><article-title>SENTRY Antimicrobial Surveillance Program Report: Latin America and Brazilian results for 1997 through 2001</article-title><source>Braz J Infect Dis</source><year>2004</year><volume>8</volume><fpage>25</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1590/S1413-86702004000100004</pub-id><pub-id pub-id-type="pmid">15286878</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Oliveira</surname><given-names>G</given-names></name><name><surname>Faria</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Mamizuka</surname><given-names>EM</given-names></name><article-title>Characterization of the Brazilian endemic clone of methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) from hospitals throughout Brazil</article-title><source>Braz J Infect Dis</source><year>2001</year><volume>5</volume><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1590/S1413-86702001000400001</pub-id><pub-id pub-id-type="pmid">11712960</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Karchmer</surname><given-names>TB</given-names></name><name><surname>Durbin</surname><given-names>LJ</given-names></name><name><surname>Simonton</surname><given-names>BM</given-names></name><name><surname>Farr</surname><given-names>BM</given-names></name><article-title>Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>J Hosp Infect</source><year>2002</year><volume>51</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1053/jhin.2002.1200</pub-id><pub-id pub-id-type="pmid">12090800</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Laupland</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Gregson</surname><given-names>DB</given-names></name><name><surname>Manns</surname><given-names>BJ</given-names></name><article-title>Cost of intensive care unit-acquired bloodstream infections</article-title><source>J Hosp Infect</source><year>2006</year><volume>63</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2005.12.016</pub-id><pub-id pub-id-type="pmid">16621137</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Crisóstomo</surname><given-names>MI</given-names></name><name><surname>Westh</surname><given-names>H</given-names></name><name><surname>Tomasz</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>DC</given-names></name><name><surname>de Lencastre</surname><given-names>H</given-names></name><article-title>The evolution of methicillin resistance in <italic>Staphylococcus aureus</italic>: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>9865</fpage><lpage>9870</lpage><pub-id pub-id-type="doi">10.1073/pnas.161272898</pub-id><pub-id pub-id-type="pmid">11481426</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>O’Neill</surname><given-names>AJ</given-names></name><article-title>New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria</article-title><source>Expert Opin Investig Drugs</source><year>2008</year><volume>17</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1517/13543784.17.3.297</pub-id><pub-id pub-id-type="pmid">18321229</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Jamil</surname><given-names>M</given-names></name><name><surname>Ul Haq</surname><given-names>I</given-names></name><name><surname>Mirza</surname><given-names>B</given-names></name><name><surname>Qayyum</surname><given-names>M</given-names></name><article-title>Isolation of antibacterial compounds from <italic>Quercus dilatata</italic> L. through bioassay guided fractionation</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2012</year><volume>11</volume><issue>Jamil M, Ul Haq I, Mirza B, Qayyum M</issue><fpage>11</fpage><pub-id pub-id-type="pmid">22554280</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Kang</surname><given-names>OH</given-names></name><name><surname>Chae</surname><given-names>HS</given-names></name><name><surname>Obiang-Obounou</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Oh</surname><given-names>YC</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Shin</surname><given-names>DW</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Kwon</surname><given-names>DY</given-names></name><article-title>Antibacterial activity of <italic>Hylomecon hylomeconoides</italic> against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Appl Biochem Biotechnol</source><year>2010</year><volume>160</volume><fpage>2467</fpage><lpage>2474</lpage><pub-id pub-id-type="doi">10.1007/s12010-009-8698-5</pub-id><pub-id pub-id-type="pmid">19578993</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Ifesan</surname><given-names>BO</given-names></name><name><surname>Hamtasin</surname><given-names>C</given-names></name><name><surname>Mahabusarakam</surname><given-names>W</given-names></name><name><surname>Voravuthikunchai</surname><given-names>SP</given-names></name><article-title>Assessment of antistaphylococcal activity of partially purified fractions and pure compounds from <italic>Eleutherine americana</italic></article-title><source>J Food Prot</source><year>2009</year><volume>72</volume><fpage>354</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">19350980</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Zuo</surname><given-names>GY</given-names></name><name><surname>Meng</surname><given-names>FY</given-names></name><name><surname>Hao</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Wang</surname><given-names>GC</given-names></name><article-title>Xu GLAntibacterial alkaloids from chelidonium majus linn (papaveraceae) against clinical isolates of methicillin-resistant Staphylococcus aureus</article-title><source>J Pharm Sci</source><year>2008</year><volume>11</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/jps.3080110206</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>EM</given-names></name><name><surname>Machado</surname><given-names>TB</given-names></name><name><surname>Leal</surname><given-names>ICR</given-names></name><name><surname>Jesus</surname><given-names>DM</given-names></name><name><surname>Damaso</surname><given-names>CRA</given-names></name><name><surname>Pinto</surname><given-names>AV</given-names></name><name><surname>de Marval</surname><given-names>MC</given-names></name><name><surname>Kuster</surname><given-names>RM</given-names></name><name><surname>dos Santos</surname><given-names>KRN</given-names></name><article-title><italic>Tabebuia avellanedae</italic> naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and <italic>in vivo</italic> dermal irritability analysis</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2006</year><volume>5</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/1476-0711-5-5</pub-id><pub-id pub-id-type="pmid">16553949</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Hashizume</surname><given-names>H</given-names></name><name><surname>Igarashi</surname><given-names>M</given-names></name><name><surname>Sawa</surname><given-names>R</given-names></name><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Akamatsu</surname><given-names>Y</given-names></name><article-title>A new type of tripropeptin with anteiso-branched chain fatty acid from <italic>Lysobacter</italic> sp. BMK333-48F3</article-title><source>J Antibiot</source><year>2008</year><volume>61</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/ja.2008.78</pub-id><pub-id pub-id-type="pmid">19160527</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Cazoto</surname><given-names>LL</given-names></name><name><surname>Martins</surname><given-names>D</given-names></name><name><surname>Ribeiro</surname><given-names>MG</given-names></name><name><surname>Durán</surname><given-names>N</given-names></name><name><surname>Nakazato</surname><given-names>G</given-names></name><article-title>Antibacterial activity of violacein against <italic>Staphylococcus aureus</italic> isolated from bovine mastitis</article-title><source>J Antibiot</source><year>2011</year><volume>64</volume><fpage>395</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1038/ja.2011.13</pub-id><pub-id pub-id-type="pmid">21364597</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Ding</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>XC</given-names></name><name><surname>Qian</surname><given-names>CD</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>O</given-names></name><name><surname>Zhan</surname><given-names>ZJ</given-names></name><name><surname>Zhao</surname><given-names>YH</given-names></name><article-title>Isolation and identification of lipopeptide antibiotics from <italic>Paenibacillus elgii</italic> B69 with inhibitory activity against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>J Microbiol</source><year>2011</year><volume>49</volume><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1007/s12275-011-1153-7</pub-id><pub-id pub-id-type="pmid">22203557</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Oliveira</surname><given-names>AG</given-names></name><name><surname>Murate</surname><given-names>LS</given-names></name><name><surname>Spago</surname><given-names>FR</given-names></name><name><surname>Lopes</surname><given-names>LP</given-names></name><name><surname>Beranger</surname><given-names>JPO</given-names></name><name><surname>San Martin</surname><given-names>JAB</given-names></name><name><surname>Nogueira</surname><given-names>MA</given-names></name><name><surname>Mello</surname><given-names>JCP</given-names></name><name><surname>Andrade</surname><given-names>CGTJ</given-names></name><name><surname>Andrade</surname><given-names>G</given-names></name><article-title>Evaluation of the antibiotic activity of extracellular compounds produced by the <italic>Pseudomonas</italic> strain against the <italic>Xanthomonas citri</italic> pv. Citri 306 strain</article-title><source>Biol Control</source><year>2011</year><volume>56</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.biocontrol.2010.10.008</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Kuroda</surname><given-names>M</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Uchiyama</surname><given-names>I</given-names></name><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Yuzawa</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>I</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Oguchi</surname><given-names>A</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Kanamori</surname><given-names>M</given-names></name><name><surname>Matsumaru</surname><given-names>H</given-names></name><name><surname>Maruyama</surname><given-names>A</given-names></name><name><surname>Murakami</surname><given-names>H</given-names></name><name><surname>Hosoyama</surname><given-names>A</given-names></name><name><surname>Mizutani-Ui</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>NK</given-names></name><name><surname>Sawano</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Kaito</surname><given-names>C</given-names></name><name><surname>Sekimizu</surname><given-names>K</given-names></name><name><surname>Hirakawa</surname><given-names>H</given-names></name><name><surname>Kuhara</surname><given-names>S</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Yabuzaki</surname><given-names>J</given-names></name><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>A</given-names></name><name><surname>Oshima</surname><given-names>K</given-names></name><name><surname>Furuya</surname><given-names>K</given-names></name><name><surname>Yoshino</surname><given-names>C</given-names></name><name><surname>Shiba</surname><given-names>T</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Ogasawara</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Hiramatsu</surname><given-names>K</given-names></name><article-title>Whole genome sequencing of methicillin-resistant <italic>Staphylococcus aureus</italic>, the major hospital pathogen</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1225</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04403-2</pub-id><pub-id pub-id-type="pmid">11418146</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Soares</surname><given-names>MJ</given-names></name><name><surname>Teixeira</surname><given-names>LA</given-names></name><name><surname>Nunes</surname><given-names>MR</given-names></name><name><surname>da Silva Carvalho</surname><given-names>MC</given-names></name><name><surname>Ferreira-Carvalho</surname><given-names>BT</given-names></name><name><surname>Figueiredo</surname><given-names>AM</given-names></name><article-title>Analysis of different molecular methods for typing methicillin-resistant <italic>Staphylococcus aureus</italic> isolates belonging to the Brazilian epidemic clone</article-title><source>J Med Microbiol</source><year>2001</year><volume>50</volume><fpage>732</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">11478678</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Cury</surname><given-names>GG</given-names></name><name><surname>Mobilon</surname><given-names>C</given-names></name><name><surname>Stehling</surname><given-names>EG</given-names></name><name><surname>Lancellotti</surname><given-names>M</given-names></name><name><surname>Ramos Mde</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>R</given-names></name><name><surname>Brocchi</surname><given-names>M</given-names></name><name><surname>Silveira</surname><given-names>WD</given-names></name><article-title>Molecular typing of methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) strains isolated in two metropolitan areas of São Paulo State, Southeast Brazil</article-title><source>Braz J Infect Dis</source><year>2009</year><volume>13</volume><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">20191190</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="book"><name><surname>Rampazo</surname><given-names>LGL</given-names></name><source>Evaluation of the effect of biological agents and their products into the incidence of citrus canker lesions</source><year>2004</year><publisher-name>Londrina, Brasil: Master thesis, Universidade Estadual de</publisher-name></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Durán</surname><given-names>N</given-names></name><name><surname>Marcato</surname><given-names>PD</given-names></name><name><surname>Alves</surname><given-names>OL</given-names></name><name><surname>de Souza</surname><given-names>GIH</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name><article-title>Mechanistic aspects of biosynthesis of silver nanoparticles by several <italic>Fusarium oxysporum</italic> strains</article-title><source>J Nanobiotechnol</source><year>2005</year><volume>3</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/1477-3155-3-1</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="book"><collab>CLSI (Clinical and Laboratory Standards Institute)</collab><source>Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard, M07-A8</source><year>2011</year><edition>8</edition><publisher-name>Wayne, PA, USA: CLSI</publisher-name></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Chin</surname><given-names>NX</given-names></name><name><surname>Weitzman</surname><given-names>I</given-names></name><name><surname>Della-Lata</surname><given-names>P</given-names></name><article-title><italic>In vitro</italic> activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against <italic>Candida</italic> species and <italic>Cryptococcus neoformans</italic></article-title><source>Antimicrob Agents Chemother</source><year>1997</year><volume>41</volume><fpage>850</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">9087504</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Hafidh</surname><given-names>RR</given-names></name><name><surname>Abdulamir</surname><given-names>AS</given-names></name><name><surname>Vern</surname><given-names>LS</given-names></name><name><surname>Abu Bakar</surname><given-names>F</given-names></name><name><surname>Abas</surname><given-names>F</given-names></name><name><surname>Jahanshiri</surname><given-names>F</given-names></name><name><surname>Sekawi</surname><given-names>Z</given-names></name><article-title>Inhibition of growth of highly resistant bacterial and fungal pathogens by a natural product</article-title><source>Open Microbiol J</source><year>2011</year><volume>5</volume><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.2174/1874285801105010096</pub-id><pub-id pub-id-type="pmid">21915230</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Chung</surname><given-names>PY</given-names></name><name><surname>Navaratnam</surname><given-names>P</given-names></name><name><surname>Chung</surname><given-names>LY</given-names></name><article-title>Synergistic antimicrobial activity between pentacyclic triterpenoids and antibiotics against <italic>Staphylococcus aureus</italic> strains</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2011</year><volume>10</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1476-0711-10-25</pub-id><pub-id pub-id-type="pmid">21658242</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Manisha</surname><given-names>D</given-names></name><name><surname>Saha</surname><given-names>K</given-names></name><name><surname>Pal</surname><given-names>NK</given-names></name><article-title>In vitro antibacterial activity of three Indian spices against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Oman Med J</source><year>2011</year><volume>26</volume><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.5001/omj.2011.80</pub-id><pub-id pub-id-type="pmid">22125725</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Fukuda</surname><given-names>D</given-names></name><name><surname>Haines</surname><given-names>AS</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Murphy</surname><given-names>AC</given-names></name><name><surname>Hothersall</surname><given-names>J</given-names></name><name><surname>Stephens</surname><given-names>ER</given-names></name><name><surname>Gurney</surname><given-names>R</given-names></name><name><surname>Cox</surname><given-names>RJ</given-names></name><name><surname>Crosby</surname><given-names>J</given-names></name><name><surname>Willis</surname><given-names>CL</given-names></name><name><surname>Simpson</surname><given-names>TJ</given-names></name><name><surname>Thomas</surname><given-names>CM</given-names></name><article-title>A natural plasmid uniquely encodes two biosynthetic pathways creating a potent anti-MRSA antibiotic</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e18031</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0018031</pub-id><pub-id pub-id-type="pmid">21483852</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Laursen</surname><given-names>JB</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><article-title>Phenazine natural products: biosynthesis, synthetic analogues, and biological activity</article-title><source>Chem Rev</source><year>2004</year><volume>104</volume><fpage>1663</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1021/cr020473j</pub-id><pub-id pub-id-type="pmid">15008629</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Mavrodi</surname><given-names>DV</given-names></name><name><surname>Blankenfeldt</surname><given-names>W</given-names></name><name><surname>Thomashow</surname><given-names>LS</given-names></name><article-title>Phenazine compounds in fluorescent <italic>Pseudomonas</italic> spp. biosynthesis and regulation</article-title><source>Ann Rev Phytopathol</source><year>2006</year><volume>44</volume><fpage>417</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1146/annurev.phyto.44.013106.145710</pub-id><pub-id pub-id-type="pmid">16719720</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Jayatilake</surname><given-names>GS</given-names></name><name><surname>Thornton</surname><given-names>MP</given-names></name><name><surname>Leonard</surname><given-names>AC</given-names></name><name><surname>Grimwade</surname><given-names>JE</given-names></name><name><surname>Baker</surname><given-names>BJ</given-names></name><article-title>Metabolites from an Antarctic sponge-associated bacterium, <italic>Pseudomonas aeruginosa</italic></article-title><source>J Nat Prod</source><year>1996</year><volume>59</volume><fpage>293</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1021/np960095b</pub-id><pub-id pub-id-type="pmid">8882433</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>EJ</given-names></name><name><surname>Kwon</surname><given-names>HC</given-names></name><name><surname>Ham</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>HO</given-names></name><article-title>6-Hydroxymethyl-1-phenazine-carboxamide and 1,6-phenazinedimethanol from a marine bacterium, <italic>Brevibacterium</italic> sp. KMD 003, associated with marine purple vase sponge antibacterial phenazines from <italic>Brevibacterium</italic> sp. KMD 003</article-title><source>J Antibiot</source><year>2009</year><volume>62</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1038/ja.2009.92</pub-id><pub-id pub-id-type="pmid">19798118</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Shanmugaiah</surname><given-names>Y</given-names></name><name><surname>Mathivanan</surname><given-names>N</given-names></name><name><surname>Varghese</surname><given-names>B</given-names></name><article-title>Purification, crystal structure and antimicrobial activity of phenazine-1-carboxamida produced by a growth-promoting biocontrol bacterium, <italic>Pseudomonas aeruginosa</italic> MML2212</article-title><source>J Appl Microbiol</source><year>2010</year><volume>108</volume><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2009.04466.x</pub-id><pub-id pub-id-type="pmid">19778345</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Chin-A-Woeng</surname><given-names>TFD</given-names></name><name><surname>Bloemberg</surname><given-names>GV</given-names></name><name><surname>Lugtenberg</surname><given-names>BJ</given-names></name><article-title>Phenazine and their role in biocontrol by <italic>Pseudomonas</italic> bacteria</article-title><source>New Phytol</source><year>2003</year><volume>157</volume><fpage>520</fpage><lpage>523</lpage></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Konaté</surname><given-names>K</given-names></name><name><surname>Mavoungou</surname><given-names>JF</given-names></name><name><surname>Lepengué</surname><given-names>AN</given-names></name><name><surname>Aworet-Samseny</surname><given-names>RRR</given-names></name><name><surname>Hilou</surname><given-names>A</given-names></name><name><surname>Souza</surname><given-names>A</given-names></name><name><surname>Dicko</surname><given-names>MH</given-names></name><name><surname>M’Batchi</surname><given-names>B</given-names></name><article-title>Antibacterial activity against β- lactamase producing Methicillin and Ampicillin-resistants <italic>Staphylococcus aureus</italic>: fractional Inhibitory Concentration Index (FICI) determination</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2012</year><volume>11</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/1476-0711-11-18</pub-id><pub-id pub-id-type="pmid">22716026</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Gribble</surname><given-names>GW</given-names></name><article-title>Commercial potential of naturally occurring halo-organics</article-title><source>Spec ChemMag</source><year>2003</year><volume>23</volume><fpage>22</fpage><lpage>24</lpage></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="other"><name><surname>Laus</surname><given-names>G</given-names></name><article-title>Biological activities of natural halogen compounds, of <italic>Studies in Natural Products Chemistry</italic>, Atta-ur-Rahman</article-title><source>Elsevier Science</source><year>2001</year><fpage>757</fpage><lpage>809</lpage></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Boyd</surname><given-names>KG</given-names></name><name><surname>Mearns-Spragg</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>DR</given-names></name><name><surname>Wright</surname><given-names>PC</given-names></name><name><surname>Burgess</surname><given-names>JG</given-names></name><article-title>Two diketopiperazines and one halogenated phenol from cultures of the marine bacterium, <italic>Pseudoalteromonas luteoviolacea</italic></article-title><source>Nat Prod Let</source><year>2000</year><volume>14</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1080/10575630008043781</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Bois/explor/OrangerV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A869 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000A869 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Bois
|area= OrangerV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.25. |  |